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Background and Objectives
• Hemophilia is an inherited genetic disorder that impairs the body's ability to form blood 
clots
• Hemophilia A (HA) is the most common form of the disorder, and is caused by a deficiency of the 
blood clotting factor VIII (FVIII)
• The hindered ability to form clots leads to an increased risk of spontaneous bleeds, 
particularly into joints (“hemarthrosis”)
• While not fatal, repeated hemarthroses are a serious complication of HA and current treatment 
aims to reduce the risk of bleeding specifically into joints
• Frequent joint bleeds prevent people with HA from being physically active, taking part in sports 
and in general, living a full life 
• Joints into which frequent bleeds occur are termed “target joints” (TJs), which require urgent 
and comprehensive treatment if permanent joint damage is to be avoided1
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Background and Objectives
• Until recently, treatment options for patients with HA have largely revolved around the 
use of FVIII products
• Recombinant FVIII (rFVIII) products may be administered “on-demand” or 
“prophylactically”, and are considered the cornerstone of severe HA treatment for 
patients without inhibitors (antibodies against FVIII)
• Standard of care for US patients with severe HA is rFVIII prophylaxis; however recent 
developments in treatment include:
• rFVIII products with an extended half-life (EHL) (rFVIII-Fc fusion protein, Eloctate® and 
PEGylated rFVIII, Adynovate®)
• Monoclonal antibody (non-factor replacement) emicizumab-kxwh (Hemlibra®)
• This study aimed to evaluate the cost-effectiveness of these prophylactic treatment 
options for severe HA patients without inhibitors from a third party US perspective
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Methods: Cost-Effectiveness Model
• Owing to the importance of joint health 
outcomes when attempting to quantify 
the cost-effectiveness of severe HA 
treatments, a cost-effectiveness model 
was constructed with health states 
based on the absence or presence of 
TJs, as well as the improvement in the 
modified hemophilia joint health score 
(mHJHS)
• Patients were categorized as having at 
least 1 TJ (“TJs”), or “No TJs”
• The model adopts a Markovian 
framework and a third-party US payer 
perspective
• Model outputs were the total costs and 
total quality-adjusted life years 






• Transitions between health states were 
determined according to calculated 
rates of TJ development or resolution 
based on published literature and 
background mortality rates2-7
• Costs relating to the use of on-demand 
and prophylactic extended half-life 
rFVIII products and emicizumab were 
included based on published weight 
data for US hemophiliacs8
• Dosing and efficacy data were 
obtained from product labels and 
published literature
• Clinical outcomes were annualized 
bleeding rate (ABR) and presence of TJs 
based on published studies2-7, 9-12
• A literature review was undertaken to 
identify evidence regarding joint health 
improvement
• Utility data were sourced from 
published literature sources13-14
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Results
• Based on the literature review, rFVIIIFc was associated with improved joint health over 
time measured by mHJHS15; no data regarding mHJHS were identified for PEGylated 
rFVIII or emicizumab
• An improvement in mHJHS of 1 point was assumed to be associated with a utility 
benefit of 0.003, and so patients receiving rFVIIIFc were assumed to have a higher 
utility of approximately 0.012 due to a 4.1-point improvement in mHJHS15
• Patients receiving PEGylated rFVIII, and emicizumab were assumed to have a 0-point 
improvement in mHJHS (based on a lack of data identified)
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Results
• The base-case analysis (Table 1) 
showed that rFVIIIFc was associated 
with the most QALYs (26.15) and 
lowest overall cost ($15.64m)
• A sensitivity analysis in which a 1-point 
improvement in mHJHS was 
associated with a utility increment of 
0.001 showed comparable results 
(Table 2)
• A further sensitivity analysis wherein 
on-demand rFVIII costs were removed 
for emicizumab patients also 
demonstrated similar results (Table 3)
Treatment Costs QALYs
rFVIIIFc $15.64m 26.15















• rFVIIIFc is the only EHL rFVIII treatment with published evidence demonstrating 
improved joint health through the mHJHS
• This cost-effectiveness analysis, which includes the impact of treatment on joint 
health, indicates that rFVIIIFc is associated with lower costs and more QALYs 
compared to PEGylated rFVIII and emicizumab
• Further data collection is required to establish the longer-term impacts of treatment on 
joint health outcomes, and consequently the cost effectiveness of alternative treatment 
options 
• In particular, the lack of available data to capture changes in joint health for comparator 
treatments is a key limitation in the analysis presented
• This study also assumed a 1 point improvement in the mHJHS is associated with a utility benefit 
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